BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with non-small cell lung cancer: Updated results from first-in-human phase I study

被引：5

作者：

Zhang, L. ^{[1
]}

Ma, Y. ^{[2
]}

Zhao, Y. ^{[3
]}

Fang, W. F.

Zhao, H. ^{[4
]}

Huang, Y. ^{[1
]}

Yang, Y. ^{[1
]}

Hou, X. ^{[1
]}

Wen, Z. ^{[5
]}

Zhang, S. ^{[6
]}

Wang, J. ^{[7
]}

Xiao, S. ^{[7
]}

Wang, H. ^{[8
]}

Zhu, H. ^{[8
]}

Olivo, M. S. ^{[9
]}

Zhu, Y. ^{[9
]}

机构：

[1] Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou, Peoples R China

[2] Sun Yat Sen Univ, Dept Clin Res, Canc Ctr, Guangzhou, Peoples R China

[3] Qingdao Univ, Med Oncol, Affiliated Hosp, Qingdao, Peoples R China

[4] Sun Yat Sen Univ, Clin Dept, Canc Ctr, Guangzhou, Peoples R China

[5] Baili Bio Chengdu Pharmaceut Co Ltd, Clin Res, Chengdu, Peoples R China

[6] Baili Bio Chengdu Pharmaceut Co Ltd, Med Affairs, Chengdu, Peoples R China

[7] Baili Bio Chengdu Pharmaceut Co Ltd, Med Pharmacol, Chengdu, Peoples R China

[8] SystImmune Inc, Biometr, Redmond, WA USA

[9] SystImmune Inc, ncol Res, Redmond, WA USA

来源：

关键词：

D O I：

10.1016/j.annonc.2023.09.2350

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1316MO

引用

页数：1